Therapeutic Response
ER positive, HER2-negative, and PIK3CA Somatic variants status confers therapeutic sensitivity to Alpelisib in combination with Fulvestrant in patients with Invasive Breast Carcinoma.
Statements
| Source and description |
|---|
ER positive, HER2-negative, and PIK3CA Somatic variants status confers therapeutic sensitivity to Alpelisib in combination with Fulvestrant in patients with Invasive Breast Carcinoma.
| Source and description |
|---|